№ lp_2_3_45242
File format: docx
Character count: 40624
File size: 966 KB
The document describes supplementary materials related to a large-scale study of recurrent copy number variations (rCNVs) and their association with psychiatric disorders, detailing the methodology and quality control steps in genetic analysis.
Year:
2023
Region / city:
Aarhus, Denmark
Topic:
Psychiatry, Genetics
Document Type:
Research Supplement
Institution:
iPSYCH Research Initiative, Aarhus University
Author:
iPSYCH Investigators
Target Audience:
Researchers, Geneticists, Psychiatrists
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / city:
Lausanne, Switzerland
Field:
Genetics
Document type:
Research article
Institution:
University of Lausanne
Authors:
Chiara Auwerx, Samuel Moix, Zoltán Kutalik, Alexandre Reymond
Target audience:
Researchers in genetics and computational biology
Period of validity:
Not applicable
Approval date:
Not applicable
Date of last modification:
Not applicable
Year:
2018
Region / city:
Northern Ireland
Topic:
Cancer survival trends, international comparison
Document type:
Research paper
Organization / institution:
NICR
Author:
Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Michel P Coleman, et al.
Target audience:
Health professionals, researchers, policymakers
Effective period:
2000–2014
Approval date:
Not specified
Date of changes:
Not specified
Journal:
Lancet
DOI:
doi.org/10.1016/S0140-6736(17)33326-3
Funders:
International contributors including Cancer Focus and Public Health Agency via NICR
Conclusion:
International differences in cancer survival exist
What this means for the service:
Northern Ireland compares well for cancer survival internationally but not when compared to similar countries in Europe.
Protocol version:
6.0
Date:
18 September 2020
Study name:
rEECur
Study design:
International randomised controlled trial
Medical condition:
Recurrent and primary refractory Ewing sarcoma
Intervention:
Chemotherapy
Sponsor:
University of Birmingham
Sponsor protocol number:
RG_13-277
CRCTU number:
SA2015
EudraCT number:
2014-000259-99
ISRCTN reference number:
ISRCTN36453794
Chief Investigator:
Dr Martin McCabe
Coordinating institution:
Cancer Research UK Clinical Trials Unit, University of Birmingham
Geographic scope:
International
Participating regions:
United Kingdom, Germany, Italy, France, Spain, Scandinavia, Australia, New Zealand, Switzerland
Target population:
Patients with recurrent or primary refractory Ewing sarcoma
Regulatory status:
Ethics and regulatory approval required per participating country
Amendment history:
Substantial amendments between 2014 and 2016
Document type:
Clinical trial protocol
Randomisation method:
Centralised online randomisation
Trial phase:
Phase II (Germany-specific limitation noted)
Year:
2024
Region / city:
Global
Theme:
Oncology, Endometrial Cancer, Pharmaceutical Submissions
Document Type:
Medical Submission
Organization / Institution:
AstraZeneca Pty Ltd
Author:
AstraZeneca Pty Ltd
Target Audience:
Medical professionals, regulatory bodies, pharmaceutical companies
Period of validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2022
Country:
Australia
Therapeutic area:
Oncology
Disease:
Endometrial cancer
Biomarker status:
Mismatch repair deficient (dMMR)
Medicine name:
Dostarlimab
Brand name:
Jemperli
Dosage form:
Solution concentrate for intravenous infusion
Sponsor:
GlaxoSmithKline Australia Pty Ltd
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission type:
Standard Re-entry submission
Requested listing:
Section 100
Comparator treatments:
Standard of care chemotherapy; pembrolizumab plus lenvatinib; pembrolizumab monotherapy
Clinical trial referenced:
GARNET
Approval status:
Provisional approval
Indication:
Recurrent or advanced endometrial cancer after platinum-containing regimen
Decision context:
PBS listing consideration
Period covered:
Up to November 2022
Year:
2024
Region / city:
United States
Theme:
Gastrointestinal pharmacology, infectious diseases, antibiotic resistance, healthcare management
Document Type:
Review
Institution:
Hackensack Palisades Medical Center, Augusta University
Author:
Nagesh VK, Tran HHV, Elias D, Kianifar Aguilar I, Sethi T, Menon A, Mansour C, Furman F, Tsotsos K, Subar T, Auda A, Sidiqui A, Lamar J, Wadhwani N, Dey S, Lo A, Atoot A, Weissman S, Sifuentes H, Bangolo AI
Target Audience:
Healthcare professionals, researchers, medical practitioners
Period of Validity:
Ongoing studies, review is relevant until new treatments emerge
Date of Approval:
2024-07-25
Date of Changes:
2024-07-21
Year:
2021
Region / City:
Not specified
Theme:
Health, Medicine
Document Type:
Medical Guidance
Organization:
Not specified
Author:
Not specified
Target Audience:
Patients on long-term steroid therapy
Period of Validity:
Not specified
Date of Approval:
Not specified
Date of Changes:
Not specified
Year:
2021
Region / City:
Chongqing, Hong Kong
Topic:
Chemical dynamic modeling, Neural networks, Attention mechanisms
Document Type:
Research article
Institution:
Chongqing University, Chongqing Technology and Business University, The Hong Kong Polytechnic University
Authors:
Yue Li, Ning Li, Jingzheng Ren, Weifeng Shen
Target Audience:
Researchers in chemical engineering, machine learning, and neural networks
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Context:
A research article on a neural network architecture (LACG) for modeling chemical dynamic processes with high accuracy.
Country:
Nigeria
Period Covered:
1981–2023
Subject:
Economic Growth and Recurrent Public Expenditure on Roads and Construction
Type of Document:
Academic Research Paper
Data Sources:
Central Bank of Nigeria Reports
Methodology:
Autoregressive Distributed Lag (ARDL) Model and Bounds Test
Variables Examined:
Real Gross Domestic Product, Recurrent Expenditure on Roads and Construction, Interest Rate, Inflation Rate
Keywords:
Economic Growth, Recurrent Expenditure, ARDL, Road and Construction
Sector Focus:
Transport Infrastructure and Public Finance
Geographical Scope:
National
Analytical Approach:
Long-run and Short-run Econometric Analysis
Time References Mentioned:
1981, 1990, 1999, 2006, 2015, 2016, 2017, 2018, 2019, 2023
Year:
2019
Region / City:
United Kingdom
Topic:
Psychological support for recurrent miscarriage
Document type:
Research study
Institution:
Not specified
Author:
Bailey et al.
Target audience:
Women with recurrent miscarriage, healthcare professionals, researchers
Period of validity:
Not applicable
Approval date:
Not specified
Date of changes:
Not specified
Year:
2016
Region / City:
Unknown
Topic:
Medical research, Pediatric Intensive Care Unit (PICU), mortality prediction
Document Type:
Research article
Organization / Institution:
Unspecified
Author:
M. Aczon, D. Ledbetter, E. Laksana, L. Ho, R. Wetzel
Target Audience:
Medical researchers, healthcare professionals
Period of Validity:
2016 onwards
Approval Date:
Unknown
Date of Changes:
Unknown
Journal:
World Journal of Gastrointestinal Oncology
Manuscript Number:
80135
Manuscript Type:
Review
Authors:
Ying-Zhe Luo; Hong Zhu
Author Affiliations:
Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Corresponding Author:
Hong Zhu
Funding:
The Key Research Projects of Science and Technology of Sichuan Province (No. 2022YFS0189)
Received:
September 18, 2022
Revised:
February 11, 2023
Accepted:
February 27, 2023
Published Online:
March 15, 2023
Volume and Issue:
Volume 15, Issue 3
Pages:
405-424
DOI:
10.4251/wjgo.v15.i3.405
Publisher:
Baishideng Publishing Group Inc.
Keywords:
Recurrent hepatocellular carcinoma; Immunotherapy; Immune checkpoint inhibitor; Chimeric antigen receptor-engineered T cell; Oncolytic virus; Tumor vaccine
Subject Area:
Oncology; Hepatology; Cancer Immunotherapy
Geographic Context:
Global epidemiology with reference to East and South-East Asia, United States, and Europe
Year:
2025
Region / City:
Not specified
Topic:
Hemochromatosis, Cardiac Arrhythmias, Thalassemia
Document Type:
Case Report
Institution:
Not specified
Author:
Not specified
Target Audience:
Healthcare professionals, researchers in cardiology
Period of Validity:
Not specified
Date of Approval:
Not specified
Date of Changes:
Not specified
Year:
2026
Region / City:
Not specified
Topic:
Cardiology, Obesity, Atrial Fibrillation
Document Type:
Research Study
Institution:
Not specified
Author:
Not specified
Target Audience:
Cardiologists, medical researchers, healthcare professionals
Study Population:
Morbidly obese patients with BMI ≥35 kg/m² undergoing AF catheter ablation
Sample Size:
217 patients
Methods:
Retrospective observational study
Primary Outcome:
Composite of recurrent atrial arrhythmias and cardiovascular hospitalizations
Risk Factors Analyzed:
BMI fluctuations, blood pressure, obstructive sleep apnea, hyperlipidemia, tobacco use, alcohol use, diabetes mellitus with HbA1c >6.5%
Follow-up Period:
Mean 2.9 years after ablation
Key Findings:
Only HbA1c >6.5% independently predicted primary outcome; timing of ablation did not affect outcomes
Conclusion:
Optimizing glycemic control is crucial for reducing recurrent atrial arrhythmias and cardiovascular hospitalizations in morbidly obese patients undergoing AF ablation
Patient Name:
Emma Smith
Age:
29
Biological Sex:
Female
Gender:
Female
Gravida/Para Status:
G4P0040
Appointment Time:
1:00 PM – 1:30 PM
Patient Status:
New Patient
Clinical Indication:
Recurrent pregnancy loss with four first-trimester miscarriages
Referral Specialty:
Adult Genetics
Relevant Medical Care:
OB/GYN, Allergy and Immunology, Pulmonology
Known Medical Conditions:
Severe nut allergy, asthma
Previous Genetic Testing:
Natera Horizon carrier screening reportedly negative for patient and partner
Family History Status:
Not formally collected
Prior Specialist Evaluation:
No previous genetics consultation; not previously evaluated by reproductive endocrinology and infertility
Differential Diagnosis:
Fetal chromosomal abnormality, parental chromosomal abnormality, uterine abnormalities, hormonal disorders, blood clotting abnormalities
Planned Evaluations:
Collection of family and medical history, targeted pregnancy history questions, assessment of prior products of conception testing
Proposed Genetic Testing:
Karyotype analysis for patient and reproductive partner
Counseling Topics:
Genetics education including genes, chromosomes, and translocations; psychosocial counseling regarding recurrent pregnancy loss
Consent Process:
Informed consent discussion including benefits, limitations, and possibility of incidental findings
Clinical Objective:
Evaluation of potential genetic causes of recurrent miscarriage and support for reproductive decision-making
Authors:
Abasiattai AM; Olisaeeke FI; Antai MMS; Ugochukwu RO; Abudu EK
Year:
2026
Journal:
Journal of Case Reports and Images in Obstetrics and Gynecology
Volume:
12
Issue:
1
Pages:
9–13
Document type:
Case report
Medical fields:
Obstetrics; Gynecology; Gynecologic oncology
Clinical topics:
Struma ovarii; Uterine fibroids; Postmenopausal patient
Patient category:
Postmenopausal women
Subject:
Coexistence of ovarian struma ovarii with recurrent uterine leiomyomas
Organization:
MedWaves, Inc.
Headquarters:
San Diego, California, United States
Medical Field:
Neurosurgery
Topic:
Microwave ablation treatment for recurrent brain tumor
Type of Document:
Medical case report and product information statement
Medical Technology:
MedWaves AveCure® Microwave Ablation System
Location of Clinical Use:
Guadalajara, Mexico
Lead Physician:
Doctor Santana
Institution:
Major hospital in Guadalajara, Mexico
Condition Treated:
Recurrent malignant meningioma
Prior Treatments:
Five microsurgeries and full radiation therapy regimen
Procedure Type:
Microwave ablation used as an adjuvant tool in neuromicrosurgery
Patient Outcome Indicator:
Karnofsky Performance Score 90 at discharge
Imaging Method:
Magnetic resonance imaging (MRI)
Hospital Discharge:
8 days after microwave ablation procedure
Regulatory Status:
FDA 510(K), CE Mark, COFEPRIS registered
Manufacturer:
MedWaves, Inc.
Intended Medical Use:
Percutaneous, laparoscopic, and intraoperative coagulation-ablation of soft tissue
Contraindicated Use:
Cardiac procedures
Contact Information:
[email protected]
Note:
, Mobile 760-807-1000
Website:
www.medwaves.com